Your browser doesn't support javascript.
loading
Holistic burden of illness in patients with endogenous Cushing's syndrome: A systematic literature review.
Page-Wilson, Gabrielle; Oak, Bhagyashree; Silber, Abigail; Okeyo, Janetricks C; Ortiz, Nancy; O'Hara, Matthew; Moloney, Stephen; Geer, Eliza B.
Afiliación
  • Page-Wilson G; Division of Endocrinology, Columbia University Irving Medical Center, New York, New York, USA.
  • Oak B; Trinity Life Sciences, Waltham, Massachusetts, USA.
  • Silber A; Trinity Life Sciences, Waltham, Massachusetts, USA.
  • Okeyo JC; Formerly at Strongbridge Biopharma plc, a wholly owned subsidiary of Xeris Biopharma Holdings, Inc., Trevose, Pennsylvania, USA.
  • Ortiz N; Formerly at Strongbridge Biopharma plc, a wholly owned subsidiary of Xeris Biopharma Holdings, Inc., Trevose, Pennsylvania, USA.
  • O'Hara M; Trinity Life Sciences, Waltham, Massachusetts, USA.
  • Moloney S; Formerly at Strongbridge Biopharma plc, a wholly owned subsidiary of Xeris Biopharma Holdings, Inc., Trevose, Pennsylvania, USA.
  • Geer EB; Multidisciplinary Pituitary and Skull Base Tumor Center, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
Endocrinol Diabetes Metab ; 7(1): e464, 2024 Jan.
Article en En | MEDLINE | ID: mdl-38124436
ABSTRACT

OBJECTIVE:

The objective of this systematic literature review (SLR) was to summarize the latest studies evaluating the burden of illness in endogenous Cushing's syndrome (CS), including the impact of CS on overall and domain-specific health-related quality of life (HRQoL) and the economic burden of CS to provide a holistic understanding of disease and treatment burden.

METHODS:

An SLR was conducted in PubMed, MEDLINE and Embase using the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) checklist to identify peer-reviewed manuscripts and conference abstracts published in English from 2015 to December 4, 2020.

RESULTS:

Forty-five publications were eligible for inclusion; data were extracted from 37 primary studies while 8 SLRs were included for reference only. Thirty-one studies reported HRQoL using validated patient reported outcome (PRO) measures in pre- or post-surgery, radiotherapy and pharmacotherapy patients. Overall, this SLR found that patients with CS have worse outcomes relative to healthy populations across specific dimensions, such as depression, despite an improvement in HRQoL post-treatment. These findings reveal that CS symptoms are not fully resolved by the existing care paradigm. Few studies report on the economic burden of CS and currently available data indicate a high direct healthcare system cost burden.

CONCLUSIONS:

Patients with CS experience a significant, complex and multifactorial HRQoL burden. Symptom-specific burden studies are sparse in the literature and the understanding of long-term CS symptomatic burden and economic burden is limited. This review intends to provide an updated reference for clinicians, payers and other stakeholders on the burden of CS as reported in published literature and to encourage further research in this area.
Asunto(s)
Palabras clave

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Síndrome de Cushing Tipo de estudio: Systematic_reviews Límite: Humans Idioma: En Revista: Endocrinol Diabetes Metab Año: 2024 Tipo del documento: Article País de afiliación: Estados Unidos

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Síndrome de Cushing Tipo de estudio: Systematic_reviews Límite: Humans Idioma: En Revista: Endocrinol Diabetes Metab Año: 2024 Tipo del documento: Article País de afiliación: Estados Unidos
...